Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Laboratory Monitoring of Mother, Fetus, and Newborn in Hemolytic Disease of Fetus and Newborn

Research output: Contribution to journalReviewResearchpeer-review

DOI

  1. Non-Invasive Fetal K Status Prediction: 7 Years of Experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Next Generation Sequencing-Based Fetal ABO Blood Group Prediction by Analysis of Cell-Free DNA from Maternal Plasma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Depletion of αβ+ T and B Cells Using the CliniMACS Prodigy: Results of 10 Graft-Processing Procedures from Haploidentical Donors

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Supportive care in pediatric acute myeloid leukemia:expert-based recommendations of the NOPHO-DB-SHIP consortium

    Research output: Contribution to journalReviewResearchpeer-review

  2. End-of-life communication: a nationwide study of bereaved parents' perceptions

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Non-Invasive Fetal K Status Prediction: 7 Years of Experience

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Abdominal Complications During Treatment for Pediatric Acute Myeloid Leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Background: Laboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn (HDFN) aims to guide clinicians and the immunized women to focus on the most serious problems of alloimmunization and thus minimize the consequences of HDFN in general and of anti-D in particular. Here, we present the current approach of laboratory screening and testing for prevention and monitoring of HDFN at the Copenhagen University Hospital in Denmark.

Summary: All pregnant women are typed and screened in the 1st trimester. This serves to identify the RhD-negative pregnant women who at gestational age (GA) of 25 weeks are offered a second screen test and a non-invasive fetal RhD prediction. At GA 29 weeks, and again after delivery, non-immunized RhD-negative women carrying an RhD-positive fetus are offered Rh immunoglobulin. If the 1st trimester screen reveals an alloantibody, antenatal investigation is initiated. This also includes RhD-positive women with alloantibodies. Specificity and titer are determined, the fetal phenotype is predicted by non-invasive genotyping based on cell-free DNA (RhD, K, Rhc, RhC, RhE, ABO), and serial monitoring of titer commences. Based on titers and specificity, monitoring with serial peak systolic velocity measurements in the fetal middle cerebral artery to detect anemia will take place. Intrauterine transfusion is given when fetal anemia is suspected. Monitoring of the newborn by titer and survival of fetal red blood cells by flow cytometry will help predict the length of the recovery of the newborn.

Original languageEnglish
JournalTransfusion Medicine and Hemotherapy (Print Edition)
Volume48
Issue number5
Pages (from-to)306-315
Number of pages10
ISSN1660-3796
DOIs
Publication statusPublished - Oct 2021

Bibliographical note

Copyright © 2021 by S. Karger AG, Basel.

ID: 70646610